- Report
- August 2025
- 190 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- October 2025
- 183 Pages
Global
From €3435EUR$3,939USD£2,979GBP
- Report
- September 2025
- 250 Pages
Global
From €3916EUR$4,490USD£3,396GBP
- Report
- February 2026
- 383 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 172 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 390 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 273 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 336 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 485 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 573 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 474 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 171 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 475 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 285 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 563 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 455 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 391 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 262 Pages
Global
From €5102EUR$5,850USD£4,425GBP
- Report
- February 2026
- 762 Pages
Global
From €5058EUR$5,800USD£4,387GBP
- Report
- February 2026
- 182 Pages
Global
From €5102EUR$5,850USD£4,425GBP

The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less Read more